What is the material of the blocker? The widely used heart blocker is a self-expanding double-disc device made of super-elastic memory metal nickel-titanium alloy wire woven and filled with polyester fibers and other coagulation-promoting substances, which is placed at the heart defect site and has good shape memory and biocompatibility. It is used for the treatment of atrial septal defects, ventricular septal defects, and patent ductus arteriosus to achieve complete closure of the heart defect. Is interventional occlusion a one-time radical procedure? Interventional occlusion is a one-time radical procedure. The blocker can be placed immediately and the epithelial cells can completely cover the blocker after 3 months to achieve a permanent cure. What should I pay attention to after interventional occlusion? Avoid strenuous activities such as bouncing for six months after surgery. Take oral aspirin for 3 to 6 months or as prescribed by the doctor. In case of viral or bacterial infection, take antiviral drugs or antibacterial agents to prevent endocarditis. Come to the hospital for regular review. Generally, ECG and cardiac ultrasound will be reviewed at 1 month, 3 months, 6 months and 1 year after surgery. How is pulmonary hypertension treated? Pulmonary hypertension is usually caused by an abnormal shunt that increases blood flow in the pulmonary circulation. Initially, pulmonary hypertension is reversible and can be restored to normal by surgically closing the abnormal shunt; however, if long-term abnormal shunt is not operated, pulmonary hypertension will slowly lead to organic lesions in the pulmonary vessels themselves, and pulmonary hypertension will become irreversible. Generally, even if the abnormal shunt is closed by surgery, the pulmonary hypertension will not be reduced, but will cause serious conditions such as reduced cardiac output, hypotension and right heart failure due to pulmonary hypertension, which will accelerate the death of the patient. In general, patients with pulmonary hypertension in precordial disease require preoperative cardiac catheterization to measure pulmonary vascular resistance to determine whether pulmonary hypertension is reversible. Irreversible pulmonary hypertension is currently treated with targeted drugs, such as the endothelin receptor antagonists bosentan, andrisentan, the phosphodiesterase inhibitors sildenafil and tadanafil, and the prostacyclin analogs vantavir (iloprost) and epoprostenol.